|
The Global Alliance for TB Drug Development is a public-private partnership driven to halt the rise and reverse the spread of the world’s oldest infectious disease by developing new, faster-acting and affordable tuberculosis medicines.
Existing drugs are forty years old and impose a daily regimen that is long and cumbersome –slowing down the control of the disease and fueling the rise of drug-resistance.
The global health community is not equipped to confront today’s triple threat: exponential rapid spread of TB infection; rise of drug-resistant strains and dangerous interaction with the raging HIV epidemic.
New, faster-acting TB medicines will yield dividends globally as shorter, simpler therapeutic and prophylactic regimens transform the fight against the disease.
By building a portfolio of promising drug candidates and forging innovative partnerships for their development, we have the strategy and the capacity to create better medicines and to register a new compound by 2010 that will:
- Shorten the duration of TB treatment or otherwise simplify its completion;
- Be effective against MDR-TB; and
- Improve the treatment of latent TB infection.
We have a two-fold bottom-line: accelerating research and development and ensuring affordability of the drugs developed, especially in the more impoverished countries with a high burden of TB. A not-for-profit venture, we connect the best practices and drive of the private sector with the resources and health equity needs of the public sector, designing new ways to leverage worldwide science and market forces for public good.
http://www.tballiance.org/
|
